| |
 |
| Uppsala, Sweden, August 8, 2006
Gyros platform for protein quantification purchased
by AstraZeneca and Cambridge Antibody Technology
Gyros announced today that it has completed the separate sales
of two microfluidic system platforms to AstraZeneca and Cambridge
Antibody Technology (CAT). |
| |
| The system sales, which took place in April 2006
prior to the acquisition of CAT by AstraZeneca, signify the growing
interest from major pharmaceutical and biopharmaceutical companies
in the benefits offered by Gyros AB’s microfluidic technology.
Gyros microfluidic platform consists of Gyrolab Bioaffy® compact
disk (CD) microlaboratories (facilitating miniaturized and integrated
protein quantification applications) and Gyrolab® Workstation
(a fully automated system for running Gyrolab Bioaffy CDs). Together
they provide a simple to use, precisely controlled solution for
processing hundreds of samples in parallel at nanoliter scale. Scientists
are able to use immunoassays with a very broad measuring range to
generate more information from less sample, improving both productivity
and efficiency.
The Process Analysis group at AstraZeneca, Södertälje,
Sweden, headed up by Dr. Anders Hagman is using Gyrolab Bioaffy
in the development of immunoassays. Dr. Hagman said, “Gyros
platform is well suited to our research applications and in particular
the development of new assays. Sample throughput and overall assay
performance have been improved, while the broad dynamic range offered
by the system has also reduced the need for sample dilutions.”
“Compared to other laboratory automation systems, Gyros system
offers a much simplified way of working. And Gyros team has provided
great support in setting up new assays at our lab”, concluded
Dr. Hagman. |
|
At Cambridge Antibody Technology, the Bioanalytical
Development group, headed up by Tim Meyers, intends to transfer
its current immunoassays onto the new Gyros platform, as well as
using it to develop new assays. Mr Meyers explained the company’s
investment decision, “The Gyros technology has been demonstrated
to enable rapid method development and increased throughput without
loss of assay performance, whilst also miniaturizing the assay.”
“Our intention is to use the Gyros platform to extend our
assay portfolio over the coming months in support of the pre-clinical
and clinical development of CAT products,” added Mr Meyers.
Jan Würtz, CEO at Gyros AB, also commented on the recent sales,
“To have major pharmaceutical and biopharmaceutical companies
recognize the inherent advantages of Gyros technology in this way
is a significant step forward for the company. We hope to see more
interest from these sectors in the future, particularly with the
introduction of Gyrolab Bioaffy 20 HC later this year. The new high-capacity
CD microlaboratories will only use 20 nL sample volume, extending
the measurement range even further and minimizing the need for sample
dilution.” |
| |
|
|
|
About AstraZeneca
AstraZeneca is a major international healthcare business engaged
in the research, development, manufacture and marketing of prescription
pharmaceuticals and the supply of healthcare services. It is one
of the world's leading pharmaceutical companies with healthcare
sales of $23.95 billion and leading positions in sales of gastrointestinal,
cardiovascular, neuroscience, respiratory, oncology and infection
products. AstraZeneca is listed in the Dow Jones Sustainability
Index (Global) as well as the FTSE4Good Index.
More information: www.astrazeneca.com/ncm.aspx
|
| |
|
|
|
About Cambridge Antibody Technology
Cambridge Antibody Technology (CAT) is a biopharmaceutical company
using its capabilities and technologies in the discovery and development
of new and innovative antibody medicines in selected therapeutic
areas to bring improvements to seriously ill patients’ lives.
Following the recent acquisition of CAT by AstraZeneca, CAT is a
subsidiary of the AstraZeneca group of companies. CAT employs around
300 people and is based near Cambridge, UK and in Palo Alto, USA.
More information: www.cambridgeantibody.com |
| |
|
|
|
About Gyros AB
Gyros is world leader in the miniaturization and integration of
laboratory applications through its proprietary microfluidics platform,
Gyrolab CD (compact disc) microlaboratory. Gyros delivers simple
to use, precisely controlled solutions for processing hundreds of
samples in parallel, generating more information from less sample
and improving lab productivity and efficiency.
Application-specific microlaboratories use a modular design offering
the potential to run different applications on a single instrument
and to create customized solutions. The company is currently focused
on two market segments: quantitative protein analysis for research,
drug discovery and development applications; and, in vitro diagnostics
for medical applications. Gyros has more than 45 employees working
at its headquarters and European sales office in Uppsala, Sweden
and its sales office in the USA.
For further information, visit www.gyros.com
or contact:
Jan Würtz, President and CEO, Gyros AB
Tel: +46 (0)18 566 400
Mobile: +46 (0)70 592 5670
jan.wurtz@gyros.com
------------------------------------------------------------------------------------------------
Statements in this press release that are not strictly historical
may be forward-looking and include risks and uncertainties. Therefore,
though based on Gyros’ current expectations, it should be
duly noted that a variety of factors could cause actual results
and experiences to differ materially from what is herein expressed.
Risks and uncertainties include, but are not limited to, risks associated
with the management of growth and international operations (including
effects of currency fluctuations), variability of operating results,
unforeseen changes in the diagnostic and pharmaceutical markets,
market competition, rapid or unexpected changes in technologies,
fluctuations in product demand, difficulties to successfully develop,
adapt, produce or commercialize products, the ability to identify
and develop new products and to differentiate products from those
of competitors, as well as various legal hazards.
------------------------------------------------------------------------------------------------
|
| |
|
|
| |
|
|
|
